Athira Pharma (ATHA) Competitors $0.40 0.00 (-1.13%) Closing price 04:00 PM EasternExtended Trading$0.39 0.00 (-0.88%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATHA vs. ANL, GANX, CVM, HOWL, IZTC, ADVM, INKT, UNCY, DRRX, and KALAShould you be buying Athira Pharma stock or one of its competitors? The main competitors of Athira Pharma include Adlai Nortye (ANL), Gain Therapeutics (GANX), CEL-SCI (CVM), Werewolf Therapeutics (HOWL), Invizyne Technologies (IZTC), Adverum Biotechnologies (ADVM), MiNK Therapeutics (INKT), Unicycive Therapeutics (UNCY), DURECT (DRRX), and KALA BIO (KALA). These companies are all part of the "pharmaceutical products" industry. Athira Pharma vs. Its Competitors Adlai Nortye Gain Therapeutics CEL-SCI Werewolf Therapeutics Invizyne Technologies Adverum Biotechnologies MiNK Therapeutics Unicycive Therapeutics DURECT KALA BIO Athira Pharma (NASDAQ:ATHA) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation. Do analysts recommend ATHA or ANL? Athira Pharma currently has a consensus price target of $0.50, suggesting a potential upside of 26.42%. Adlai Nortye has a consensus price target of $9.00, suggesting a potential upside of 437.12%. Given Adlai Nortye's higher possible upside, analysts plainly believe Adlai Nortye is more favorable than Athira Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athira Pharma 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Adlai Nortye 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has preferable valuation and earnings, ATHA or ANL? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAthira PharmaN/AN/A-$96.94M-$1.55-0.26Adlai NortyeN/AN/A-$51.87MN/AN/A Do institutionals and insiders have more ownership in ATHA or ANL? 57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are held by institutional investors. 22.1% of Athira Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, ATHA or ANL? Athira Pharma has a beta of 3, suggesting that its stock price is 200% more volatile than the S&P 500. Comparatively, Adlai Nortye has a beta of -0.95, suggesting that its stock price is 195% less volatile than the S&P 500. Is ATHA or ANL more profitable? Adlai Nortye's return on equity of 0.00% beat Athira Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Athira PharmaN/A -139.40% -106.84% Adlai Nortye N/A N/A N/A Does the media prefer ATHA or ANL? In the previous week, Athira Pharma and Athira Pharma both had 1 articles in the media. Adlai Nortye's average media sentiment score of 1.88 beat Athira Pharma's score of 1.87 indicating that Adlai Nortye is being referred to more favorably in the news media. Company Overall Sentiment Athira Pharma Very Positive Adlai Nortye Very Positive SummaryAdlai Nortye beats Athira Pharma on 5 of the 8 factors compared between the two stocks. Get Athira Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHA vs. The Competition Export to ExcelMetricAthira PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.78M$3.10B$5.78B$9.80BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-0.2621.0831.2626.59Price / SalesN/A364.13454.13168.41Price / CashN/A44.6737.7359.36Price / Book0.498.0910.046.68Net Income-$96.94M-$54.08M$3.27B$265.59M7 Day Performance0.28%2.25%3.17%3.42%1 Month Performance-4.19%3.41%4.34%1.09%1 Year Performance-87.98%18.61%44.12%23.84% Athira Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHAAthira Pharma3.7539 of 5 stars$0.40-1.1%$0.50+26.4%-87.9%$15.78MN/A-0.2640Positive NewsANLAdlai Nortye1.6568 of 5 stars$1.77+4.8%$9.00+408.2%-43.5%$62.36M$5M0.00127Positive NewsGap DownGANXGain Therapeutics2.1939 of 5 stars$1.77+2.3%$7.80+340.7%+42.0%$62.19M$50K-2.8120News CoverageAnalyst RevisionHigh Trading VolumeCVMCEL-SCI0.6633 of 5 stars$8.92+2.5%N/A-61.2%$61.39MN/A-18.5843News CoverageGap DownHOWLWerewolf Therapeutics3.1659 of 5 stars$1.33flat$8.33+526.6%-41.7%$60.82M$1.88M-0.8140News CoverageAnalyst ForecastIZTCInvizyne TechnologiesN/A$9.70-2.9%N/AN/A$60.64MN/A0.0029ADVMAdverum Biotechnologies4.1255 of 5 stars$2.93+2.4%$19.75+574.1%-58.0%$60.01M$1M-0.37190INKTMiNK Therapeutics2.7441 of 5 stars$14.62-1.9%$37.50+156.5%+95.0%$59.43MN/A-5.0830Gap DownUNCYUnicycive Therapeutics2.6847 of 5 stars$4.08-13.2%$60.00+1,370.6%+19.8%$59.41M$680K-0.999Trending NewsHigh Trading VolumeDRRXDURECT1.8412 of 5 stars$1.90-0.5%N/A+35.0%$59.31M$2.03M-19.0080KALAKALA BIO3.5369 of 5 stars$8.58+3.1%$13.00+51.5%+59.2%$58.42MN/A-1.2630Positive News Related Companies and Tools Related Companies ANL Competitors GANX Competitors CVM Competitors HOWL Competitors IZTC Competitors ADVM Competitors INKT Competitors UNCY Competitors DRRX Competitors KALA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHA) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athira Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access